comparison of sequential-concomitant hybrid to sequential therapy in h.pylori eradication rate

Not Applicable

• Conditions: PUD(H.PYLORI ERADICATION REGIMEN).; GASTRIC ULCER,DUODENAL ULCER,PEPTIC ULCER DISEASE, GASRTRODUODENITIS; K25.9,K26.

• Registration Number: IRCT201110312499N2
• Lead Sponsor: Vice Chancellor For Research, Mazandaran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 296

Inclusion Criteria

age more than 18 years and less than 80 years with duodenal or gastric ulcers; duodenal or gastric erosions and helicobacter pylori positivity. Exclusion criteria: Previous history of receiving any H.pylori eradication regimen, Taking H2 blocker, proton pump inhibitor, Bismuth or Antibiotics during the 2 weeks prior to the study, Taking anticoagulants, ketoconazole or corticosteroids, History of gastric or esophageal surgery, Severe cardiovascular, pulmonary or endocrine disease, Renal failure, Hepatic diseases, Malignancies, Alcoholism, Pregnancy or breast feeding

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Helicobacter pylori eradication rate. Timepoint: 2 months after the completion of treatment course. Method of measurement: urease breath test.

Secondary Outcome Measures

Name	Time	Method
Side effects of drugs. Timepoint: daily recording during and after the treatment course. Method of measurement: classifying as mild, moderate or severe side effects.